Silvey S, Patel N, Khoruts A, Bajaj JS, et al. Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two National US-based cohorts. Gastroenterology 2025 Mar 21:S0016-5085(25)00535.
PMID: 40122471